Amicus Therapeutics Shares Outstanding 2007-2021 | FOLD

Amicus Therapeutics shares outstanding from 2007 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Amicus Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 259
2019 240
2018 186
2017 153
2016 134
2015 110
2014 74
2013 51
2012 46
2011 35
2010 28
2009 23
2008 22
2007 13
2006 1
2005 0
Amicus Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 266
2021-03-31 264
2020-12-31 259
2020-09-30 259
2020-06-30 258
2020-03-31 257
2019-12-31 240
2019-09-30 255
2019-06-30 238
2019-03-31 214
2018-12-31 186
2018-09-30 189
2018-06-30 189
2018-03-31 176
2017-12-31 153
2017-09-30 161
2017-06-30 143
2017-03-31 143
2016-12-31 134
2016-09-30 141
2016-06-30 129
2016-03-31 125
2015-12-31 110
2015-09-30 119
2015-06-30 100
2015-03-31 96
2014-12-31 74
2014-09-30 79
2014-06-30 67
2014-03-31 64
2013-12-31 51
2013-09-30 50
2013-06-30 50
2013-03-31 50
2012-12-31 46
2012-09-30 49
2012-06-30 47
2012-03-31 38
2011-12-31 35
2011-09-30 35
2011-06-30 35
2011-03-31 34
2010-12-31 28
2010-09-30 28
2010-06-30 28
2010-03-31 24
2009-12-31 23
2009-09-30 23
2009-06-30 23
2009-03-31 23
2008-12-31 22
2008-09-30 23
2008-06-30 22
2008-03-31 22
2007-12-31 13
2007-09-30 22
2007-06-30 7
2007-03-31 1
2006-09-30 1
2006-06-30 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.959B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71